Related Experiment Videos
Man-made superantigens: Tumor-selective agents for T-cell-based therapy.
Dohlsten1, Kalland, Gunnarsson
1Pharmacia & Upjohn, Lund Research Center, Scheelevägen 22, S-223 63 Lund, Sweden
Advanced Drug Delivery Reviews
|June 6, 2000
Summary
Engineered superantigens (SAgs) target T-cells to tumors, enhancing cancer therapy. Mutating the MHC II binding site reduces toxicity while maintaining anti-tumor immunity, improving safety and efficacy.
Area of Science:
- Immunology
- Protein Engineering
- Oncology
Background:
- Superantigens (SAgs) are potent immune stimulants.
- SAgs bind Major Histocompatibility Complex Class II (MHC II) on antigen-presenting cells, activating T-cells.
Purpose of the Study:
- To engineer a novel superantigen (SAg) for targeted cancer therapy.
- To improve the safety and efficacy of SAg-based immunotherapies.
Main Methods:
- Genetically linked tumor-specific antibody fragments to Staphylococcal enterotoxin A (SEA).
- Utilized structure-based drug design to mutate the MHC II binding site of SEA.
- Evaluated Fab-SEA fusion proteins and mutants in animal models for tumor targeting and T-cell activation.
Main Results:
- Fab-SEA fusion proteins targeted solid tumors and mediated T-cell-dependent tumor eradication.
- Native Fab-SEA caused dose-limiting toxicity due to systemic immune activation.
- Mutated Fab-SEA showed reduced MHC II retention and toxicity, with a >100-fold improved therapeutic window.
Conclusions:
- Protein engineering can convert toxic SAgs into safe, tumor-specific immunotherapeutic agents.
- Mutated SAgs offer improved targeting and reduced systemic toxicity for cancer treatment.